The time to offer treatments for COVID-19.

Autor: Ngo BT; Keck USC School of Medicine, Los Angeles, USA.; The Rose Salter Medical Research Foundation, Newport Coast, USA., Marik P; Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA., Kory P; Pulmonary and Critical Care Medicine, Aurora St. Luke's Medical Center, Milwaukee, USA., Shapiro L; Department of Internal Medicine, Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by the Emily Foundation, Boston, USA., Thomadsen R; Department of Marketing, Washington University, St. Louis, USA., Iglesias J; Department of Internal Medicine, Jersey Shore University Medical Center, Hackensack Meridian School of Medicine at Seton Hall, Neptune, USA., Ditmore S; Health Reporting, Parkchester Times, USA., Rendell M; The Rose Salter Medical Research Foundation, Newport Coast, USA., Varon J; United Memorial Medical Center, University of Texas School of Medicine, Houston, USA., Dubé M; Keck USC School of Medicine, Los Angeles, USA., Nanda N; Keck USC School of Medicine, Los Angeles, USA., In G; Keck USC School of Medicine, Los Angeles, USA., Arkfeld D; Keck USC School of Medicine, Los Angeles, USA., Chaudhary P; Keck USC School of Medicine, Los Angeles, USA., Campese VM; Keck USC School of Medicine, Los Angeles, USA., Hanna DL; Keck USC School of Medicine, Los Angeles, USA., Sawcer DE; Keck USC School of Medicine, Los Angeles, USA., Ehresmann G; Keck USC School of Medicine, Los Angeles, USA., Peng D; Keck USC School of Medicine, Los Angeles, USA., Smogorewski M; Keck USC School of Medicine, Los Angeles, USA., Armstrong A; Keck USC School of Medicine, Los Angeles, USA., Dasgupta R; Keck USC School of Medicine, Los Angeles, USA., Sattler F; Keck USC School of Medicine, Los Angeles, USA., Brennan-Rieder D; CoronaTracker Community Research Group, Canada., Mussini C; Department of Infectious Disease, University of Modena and Reggio Emilia, Modena, Italy., Mitja O; Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Badalona, Spain., Soriano V; Director, Centro Medico, UNIR Health Sciences School & Medical Center, Madrid, Spain., Peschanski N; Department of Emergency Medicine, UniversityHospital of Rennes, Rennes, France., Hayem G; Department of Rheumatology, Hôpital Paris Saint-Joseph, Paris, France., Confalonieri M; Department of Respiratory Diseases, Azienda Ospedaliero-Universitaria Di Trieste, Trieste, Italia., Piccirillo MC; Department of Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italia., Lobo-Ferreira A; Unidade De Investigação Cardiovascular (Unic), Faculdade De Medicina, Da Universidade Do Porto, Centro Hospitalar Universitário De São João, Porto, and Hospital Rainha Santa Isabel, Marco De Canaveses, Portugal., Bello Rivero I; Department of Clinical Investigations, Center for Genetic Engineering and Biotechnology, Havana, Cuba., Turkia M; Qualitative Research, Helsinki, Finland., Vinjevoll EH; Department of Anesthesiology, Volda Hospital HMR, Norway., Griffin D; Department of Internal Medicine, Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by the Emily Foundation, Boston, USA.; Department of Internal Medicine and Department of Biochemistry and Molecular Biophysics, ProHEALTH, an OPTUM Company, Columbia University, College of Physicians and Surgeons, USA., Hung IF; Department of Internal Medicine, Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by the Emily Foundation, Boston, USA.
Jazyk: angličtina
Zdroj: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 May; Vol. 30 (5), pp. 505-518. Date of Electronic Publication: 2021 Apr 23.
DOI: 10.1080/13543784.2021.1901883
Abstrakt: Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease. Methods: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results. Results: As of 2/15/2021, we found 111 publications reporting findings on 14 classes of agents, and 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care. Remdesivir and high titer convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries. Expert Opinion : Vaccines and antibodies are highly antigen specific, and new SARS-Cov-2 variants are appearing. We call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients in parallel with universal vaccination.
Databáze: MEDLINE